Tag: Pfizer
-

Vaxcyte’s VAX-31 Meets Phase 3 Endpoints Versus Prevnar 20 and Capvaxive
Vaxcyte’s VAX-31 met all prespecified primary endpoints in the Phase 3 OPUS-1 trial, supporting its potential as a broader adult pneumococcal vaccine. The candidate includes all 20 Prevnar 20 serotypes plus 11 additional serotypes.
-

Pfizer Lands Metsera Acquisition After Novo Nordisk Bows Out of $10 B Bidding War
Pfizer’s acquisition of Metsera secures a high-potential obesity-drug pipeline — but because Metsera’s assets are early-stage, the deal carries meaningful regulatory and execution risk.
-

The Battle for Metsera: Pfizer and Novo Nordisk in a Fierce Takeover War
As the race for next-generation obesity treatments intensifies, two global pharma giants — Pfizer and Novo Nordisk — are locked in a fierce takeover battle over Metsera, a promising biotech with breakthrough GLP-1 assets. What began as a merger deal has escalated into a high-stakes legal and strategic war.